| 37.23 -0.89 (-2.33%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.95  |
1-year : | 52.5 |
| Resists | First : | 38.49 |
Second : | 44.95 |
| Pivot price | 34.7 |
|||
| Supports | First : | 33.03 |
Second : | 29.67 |
| MAs | MA(5) : | 37.44 |
MA(20) : | 33.95 |
| MA(100) : | 34.52 |
MA(250) : | 31.54 |
|
| MACD | MACD : | 1.3 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 93.8 |
D(3) : | 93.1 |
| RSI | RSI(14): 63.4 |
|||
| 52-week | High : | 46 | Low : | 22.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AGIO ] has closed below upper band by 28.6%. Bollinger Bands are 72.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.53 - 38.75 | 38.75 - 38.95 |
| Low: | 36.26 - 36.5 | 36.5 - 36.71 |
| Close: | 36.89 - 37.27 | 37.27 - 37.61 |
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Thu, 29 Oct 2026
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Wed, 28 Oct 2026
After a $25.01 option exercise, Sarah Gheuens sells 7,866 Agios Pharmaceuticals (AGIO) shares. - Stock Titan
Mon, 26 Oct 2026
A 7,866-share sale is planned by Agios (NASDAQ: AGIO) officer Sarah Gheuens. - Stock Titan
Fri, 23 Oct 2026
Agios Pharmaceuticals, Inc. Estimates – NASDAQ:AGIO - TradingView
Tue, 06 Oct 2026
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView
Thu, 20 Aug 2026
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 115.4 (%) |
| Shares Short | 7,020 (K) |
| Shares Short P.Month | 7,540 (K) |
| EPS | -7.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.2 |
| Profit Margin | 0 % |
| Operating Margin | -247.1 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -34.4 % |
| Qtrly Rev. Growth | 259.2 % |
| Gross Profit (p.s.) | -4.47 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | -7.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -361 (M) |
| Levered Free Cash Flow | -275 (M) |
| PE Ratio | -5.32 |
| PEG Ratio | 0 |
| Price to Book value | 2.16 |
| Price to Sales | 22.6 |
| Price to Cash Flow | -6.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|